1. Aldenhoven, M., Barlo, N. P., and Sanders, C. J. (2006). Therapeutic strategies for epidemic Kaposi’s sarcoma. Int J STD AIDS 17, 571–578.
2. Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., Landre, J., Pluderi, M., Tomei, G., Villani, R., et al. (2001). Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61, 7501–7506.
3. Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., and Kerbel, R. S. (2003). Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63, 4342–4346.
4. Blansfield, J. A., Caragacianu, D., Alexander, H. R., 3rd, Tangrea, M. A., Morita, S. Y., Lorang, D., Schafer, P., Muller, G., Stirling, D., Royal, R. E., et al. (2008). Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14, 270–280.
5. Bocci, G., Falcone, A., Fioravanti, A., Orlandi, P., Di Paolo, A., Fanelli, G., Viacava, P., Naccarato, A. G., Kerbel, R. S., Danesi, R., et al. (2008). Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98, 1619–1629.